Oncology CRO Services
Delays in oncology drug development come at a cost for everyone. When success depends on reaching the market faster, you’ll need a targeted approach built on reliable relationships with experienced sites — and a team that will stick with you for the long haul.
21
drug approvals
60
10,000
sites in 62 countries
Oncology Pivotal Trial Solutions
The number of oncology trials has increased by an average of 250 trials per year since 2000.1 At the same time, emerging treatment modalities, including multispecific antibodies, radiopharmaceuticals, cell therapies, and antibody-drug conjugates (ADCs), are transforming the treatment landscape.
As the complexity of the oncology clinical trial landscape grows, so does the importance of having an experienced, dedicated guide by your side. PSI prioritizes your study with 30 years of unwavering commitment to on-time delivery, a tenured team with one of the lowest turnover rates in the industry, and a unique approach to site support that maximizes speed while ensuring quality.
Ditch the countless change orders and generic approaches of large CROs. PSI’s indication-specific experts will identify the optimal path for your study and provide true stability where it matters most.
PSI Oncology Highlights
- Leading the industry in radiopharmaceutical research
- Delivered 10% of FDA-approved drugs in oncology
- 90% of project managers have oncology experience
- 60 board-certified oncologists
- Proactive expert-led training courses in emerging technologies and methodologies for clinical operations
A proven track record of delivering oncology trials on time
Targets
- PSMA, SSTR, FAP, and other radioligand therapy targets
- PD-1 and other immune checkpoints
- EGFR, HER2, JAK2, KRAS, and other oncogenic receptors
- CD19, CD30, EZH2, and other tumor-specific markers
- BRCA and other HRD-associated alterations
- Hormonal receptor targets (ER/AR)
Drug Classes
- Antibody drug conjugates (ADCs)
- Bispecific/multispecific antibodies
- Immunotherapies (including checkpoint inhibitors, cell therapies, cytokines)
- Radioligand therapies (in diagnostic and therapeutic settings)
- Small molecule inhibitors
- Therapeutic proteins and vaccines
- Combination therapies
- Supportive care products
- Hormonal therapy
- Biosimilars
Indications
- Breast cancer
- Gastrointestinal (GI) cancers
- Genitourinary (GU) cancers
- Gynecologic cancers
- Head and neck cancer
- Lung cancer
- Leukemias
- Lymphomas
- Multiple myeloma
- Myeloproliferative neoplasms (MPNs)
- Neuroendocrine tumors (NETs)
- Sarcomas
- Skin cancer
- Supportive care indications in oncology
Specialized Oncology Trial Support Services
In-depth Site Identification and Feasibility
Precision medicine studies require precision-targeted sites, not just during the study planning phase but throughout the trial. With the support of PSI’s GenAI-powered VISIONAL™ feasibility/financial planning platform, your project team can adapt quickly to shifting standards of care, global variability in drug access, and the demands of emerging treatment modalities.
Our sponsors have successfully partnered with PSI to identify the optimal country and site mix for their pivotal studies: exploring Latin America for radiopharma; expanding their ADC studies to untapped regions in APAC and less saturated site networks in the US; and going beyond the busiest cell therapy centers in Europe and North America.
Comprehensive Expertise Matched to Each Study
Have you felt the frustrations of working with a CRO that just wasn’t aligned with your study? At PSI, we recognize that every oncology program requires a unique approach. With our team of in-house board-certified oncologists working as medical monitors, you can be confident your trial is supported by professionals who understand the nuances of the specific disease, whether it’s breast cancer, lung cancer, or rare tumors.
PSI’s Scientific Advisory Board extends your expertise through relationships with over 40 oncology key opinion leaders, including specialists in radiation oncology and cell therapy, to help guide strategic decisions and align your protocol with the latest advances and treatment paradigms.
Site Relationships Powering Oncology Clinical Research
An average oncology center may have dozens of active clinical trials at once.2 Site staff are busy, stretched thin, and often overwhelmed. Even groundbreaking science can fall flat if the team doesn’t have capacity. The question is: will they prioritize your study—or push it to the back of the line?
That’s where it’s important to have a true partner who will help lighten the load, making it easier for sites to give your study the attention it deserves:
- Tailored resources and project-specific training to ensure quality and consistency
- Dedicated oncology site support specialists to provide assistance throughout the process
- One-on-one support with navigating imaging and central radiology requirements to speed up site qualification
- Dedicated enrollment plans and pre-enrollment and patient pathways to help teams understand where patients will funnel into the sites
We invite only the most elite, top-performing sites and investigators to join PSI’s Valued Site Database™. These sites share a commitment to optimizing access to eligible patients, decreasing start-up times and administrative burden, and enabling multiple efficiencies for pivotal oncology trials. The Valued Site Database includes leading academic centers, community cancer centers, private oncology practices, and site networks, all with the detailed site knowledge you need to identify the right partners for your studies.
1. Izarn, F., Henry, J., Besle, S., Ray-Coquard, I., Blay, J.-Y., Allignet, B., & 6. (2024, December 18). Globalization of clinical trials in oncology: A worldwide quantitative analysis. ESMO Open. https://www.sciencedirect.com/science/article/pii/S2059702924018568
2. Kasner M, Fritsche AH, Leong MC, et al. North American Cancer Center Clinical Research Capacity and benchmarking in the postpandemic era. JCO Oncology Practice. 2024;20(12):1612-1619. doi:10.1200/op.24.00164
Connect with PSI’s oncology team
Your team of oncology experts is just a click away. Get in touch today.
Trusted to Deliver
When you partner with PSI, you work with a team recognized by independent industry organizations and sponsor surveys for what matters most in clinical research: expertise, consistent operational excellence, and reliable delivery.
